Transgene is designing and developing next-generation immunotherapeutics against cancer
Innovative technologies
Push the boundaries of immunotherapy
Transgene combines cutting-edge technologies, a multidisciplinary team and a prestigious international network.
Discover our myvac® platform
Discover our invir.IO® platform
TG4050
One patient, one cancer, one vaccine
TG4050 is an individualized neoantigen cancer vaccines from Transgene’s myvac® platform, based on multiple advanced genetic engineering technologies and cutting-edge artificial intelligence capabilities.
TG4050 is being evaluated in a Phase I/II clinical trial.
TG4050 video
Watch Alessandro Riva presenting first clinical benefits of neoantigen cancer vaccine, TG4050, in head & neck cancer at AACR 2024
Oncolytic viruses
A new generation of products
These innovative multifunctional OVs, from Transgene’s invir.IO® platform, are able to modulate the tumor microenvironment to better attack cancer.
Oncolytic viruses video
TG4001
A therapeutic vaccine in Phase II
TG4001 targets HPV-induced anogenital cancers.
More information
Three therapeutic approaches
Transgene’s immunotherapies harness the mechanisms of the immune response to enable the patient’s body to fight against disease.
- aacr
AACR 2024
Transgene et NEC Present Proof of Principle Data for TG4050 in Head & Neck Cancer
Donwload Press release (PDF)
Interview of Alessandro Riva
Donwload the Poster (PDF) - Presentation
Transgene in a nutshell
Corporate Presentation
Universal Registration Document
Press releases
- June 3, 2024 - Transgene – First Patient Enrolled in Phase II Part of Randomized Phase I/II Trial Evaluating Lead Cancer Vaccine TG4050 in Head and Neck Cancer
- May 15, 2024 - Transgene’s Combined General Meeting of May 15, 2024
- May 14, 2024 - Transgene provides business and financial update for Q1 2024
Last publications
- April 9, 2024 - Personalized vaccine TG4050 induces polyepitopic immune responses against private neoantigens in resected HPV negative head and neck cancers
- August 29, 2023 - Phase Ib/II trial of tipapkinogene sovacivec (TG4001), a therapeutic human papillomavirus 16-vaccine, in combination with avelumab in patients with advanced human papillomavirus 16-positive cancers
- May 26, 2023 - Safety and Immunogenicity of TG4050; a personalized cancer vaccine in head and neck carcinoma
